88 related articles for article (PubMed ID: 22908169)
1. Population pharmacokinetics of piperacillin at two dose levels: influence of nonlinear pharmacokinetics on the pharmacodynamic profile.
Landersdorfer CB; Bulitta JB; Kirkpatrick CM; Kinzig M; Holzgrabe U; Drusano GL; Stephan U; Sörgel F
Antimicrob Agents Chemother; 2012 Nov; 56(11):5715-23. PubMed ID: 22908169
[TBL] [Abstract][Full Text] [Related]
2. Nonlinear pharmacokinetics of piperacillin in healthy volunteers--implications for optimal dosage regimens.
Bulitta JB; Kinzig M; Jakob V; Holzgrabe U; Sörgel F; Holford NH
Br J Clin Pharmacol; 2010 Nov; 70(5):682-93. PubMed ID: 21039762
[TBL] [Abstract][Full Text] [Related]
3. Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers.
Bulitta JB; Duffull SB; Kinzig-Schippers M; Holzgrabe U; Stephan U; Drusano GL; Sörgel F
Antimicrob Agents Chemother; 2007 Jul; 51(7):2497-507. PubMed ID: 17485505
[TBL] [Abstract][Full Text] [Related]
4. Developmental pharmacokinetics of piperacillin and tazobactam using plasma and dried blood spots from infants.
Cohen-Wolkowiez M; Watt KM; Zhou C; Bloom BT; Poindexter B; Castro L; Gao J; Capparelli EV; Benjamin DK; Smith PB
Antimicrob Agents Chemother; 2014 May; 58(5):2856-65. PubMed ID: 24614369
[TBL] [Abstract][Full Text] [Related]
5. Identification of optimal renal dosage adjustments for traditional and extended-infusion piperacillin-tazobactam dosing regimens in hospitalized patients.
Patel N; Scheetz MH; Drusano GL; Lodise TP
Antimicrob Agents Chemother; 2010 Jan; 54(1):460-5. PubMed ID: 19858253
[TBL] [Abstract][Full Text] [Related]
6. Piperacillin concentration in relation to therapeutic range in critically ill patients--a prospective observational study.
Zander J; Döbbeler G; Nagel D; Maier B; Scharf C; Huseyn-Zada M; Jung J; Frey L; Vogeser M; Zoller M
Crit Care; 2016 Apr; 20():79. PubMed ID: 27039986
[TBL] [Abstract][Full Text] [Related]
7. Population Pharmacokinetics of Piperacillin in Sepsis Patients: Should Alternative Dosing Strategies Be Considered?
Andersen MG; Thorsted A; Storgaard M; Kristoffersson AN; Friberg LE; Öbrink-Hansen K
Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29507062
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of ceftolozane/tazobactam in healthy volunteers, subjects with varying degrees of renal function and patients with bacterial infections.
Chandorkar G; Xiao A; Mouksassi MS; Hershberger E; Krishna G
J Clin Pharmacol; 2015 Feb; 55(2):230-9. PubMed ID: 25196976
[TBL] [Abstract][Full Text] [Related]
9. Comparison of pharmacokinetics software for therapeutic drug monitoring of piperacillin in patients with severe infections.
Rodríguez-Báez AS; Jiménez-Meseguer M; Milán-Segovia RDC; Romano-Moreno S; Barcia E; Ortiz-Álvarez A; García-Díaz B; Medellín-Garibay SE
Eur J Hosp Pharm; 2024 Apr; 31(3):201-206. PubMed ID: 36126967
[TBL] [Abstract][Full Text] [Related]
10. Understanding adefovir pharmacokinetics as a component of a transporter phenotyping cocktail.
Dong Q; Chen C; Taubert M; Bilal M; Kinzig M; Sörgel F; Scherf-Clavel O; Fuhr U; Dokos C
Eur J Clin Pharmacol; 2024 Jul; 80(7):1069-1078. PubMed ID: 38546841
[TBL] [Abstract][Full Text] [Related]
11. Balancing the scales: achieving the optimal beta-lactam to beta-lactamase inhibitor ratio with continuous infusion piperacillin/tazobactam against extended spectrum beta-lactamase producing
Cojutti PG; Pai MP; Tonetti T; Siniscalchi A; Viale P; Pea F
Antimicrob Agents Chemother; 2024 Apr; 68(4):e0140423. PubMed ID: 38411995
[TBL] [Abstract][Full Text] [Related]
12. Individualized antibiotic dosage regimens for patients with augmented renal clearance.
Shi AX; Qu Q; Zhuang HH; Teng XQ; Xu WX; Liu YP; Xiao YW; Qu J
Front Pharmacol; 2023; 14():1137975. PubMed ID: 37564179
[No Abstract] [Full Text] [Related]
13. Predictive Factors of Piperacillin Exposure and the Impact on Target Attainment after Continuous Infusion Administration to Critically Ill Patients.
Martínez-Casanova J; Esteve-Pitarch E; Colom-Codina H; Gumucio-Sanguino VD; Cobo-Sacristán S; Shaw E; Maisterra-Santos K; Sabater-Riera J; Pérez-Fernandez XL; Rigo-Bonnin R; Tubau-Quintano F; Carratalà J; Padullés-Zamora A
Antibiotics (Basel); 2023 Mar; 12(3):. PubMed ID: 36978398
[TBL] [Abstract][Full Text] [Related]
14. Population Pharmacokinetics of Piperacillin/Tazobactam Across the Adult Lifespan.
Hemmersbach-Miller M; Balevic SJ; Winokur PL; Landersdorfer CB; Gu K; Chan AW; Cohen-Wolkowiez M; Conrad T; An G; Kirkpatrick CMJ; Swamy GK; Walter EB; Schmader KE
Clin Pharmacokinet; 2023 Jan; 62(1):127-139. PubMed ID: 36633812
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Piperacillin and Tazobactam Pharmacokinetics in Critically Ill Patients with Trauma or with Burn.
Selig DJ; Akers KS; Chung KK; Kress AT; Livezey JR; Por ED; Pruskowski KA; DeLuca JP
Antibiotics (Basel); 2022 May; 11(5):. PubMed ID: 35625262
[TBL] [Abstract][Full Text] [Related]
16. Using a Validated Population Pharmacokinetic Model for Dosing Recommendations of Continuous Infusion Piperacillin for Critically Ill Adult Patients.
El-Haffaf I; Guilhaumou R; Velly L; Marsot A
Clin Pharmacokinet; 2022 Jun; 61(6):895-906. PubMed ID: 35344155
[TBL] [Abstract][Full Text] [Related]
17. Personalized Antibiotic Therapy for the Critically Ill: Implementation Strategies and Effects on Clinical Outcome of Piperacillin Therapeutic Drug Monitoring-A Descriptive Retrospective Analysis.
Nikolas S; Thorsten R; Max K; Patrick M; Markus K; Güzin S; Oliver SC; Alexander S; Andreas P; Kerstin H
Antibiotics (Basel); 2021 Nov; 10(12):. PubMed ID: 34943664
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of Commonly Used Medications in Children Receiving Continuous Renal Replacement Therapy: A Systematic Review of Current Literature.
Dubinsky S; Watt K; Saleeb S; Ahmed B; Carter C; Yeung CHT; Edginton A
Clin Pharmacokinet; 2022 Feb; 61(2):189-229. PubMed ID: 34846703
[TBL] [Abstract][Full Text] [Related]
19. Piperacillin-Tazobactam in Intensive Care Units: A Review of Population Pharmacokinetic Analyses.
El-Haffaf I; Caissy JA; Marsot A
Clin Pharmacokinet; 2021 Jul; 60(7):855-875. PubMed ID: 33876381
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
